Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of
multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance
therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to
evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and
capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal
carcinoma.